Master bibliography — ischemic heart disease

Generated from the condition citation graph. Original records were live-resolved on 2026-08-28 and re-audited on 2026-08-30; the 65 topic-specific additions were live-resolved through PubMed E-utilities on 2026-09-02, and every record was re-resolved during the independent audit on 2026-09-02. One record appears once; cited by records the graph at the time each section was generated.

Coverage: 252 deduplicated resolved PubMed records; 251 are cited by wiki pages.

Burden and epidemiology

• Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. PMID 17387127 — tags: [INDEX, OPEN-QUESTIONS, STATISTICS, boden-2007-courage, clinical-trials-landscape, overview, pathophysiology-and-plaque-biology, patient-experience-and-advocacy, revascularization-pci-and-cabg, stable-cad-management] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/boden-2007-courage.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Antithrombotic Trialists' (ATT) Collaboration, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. PMID 19482214 — tags: [antithrombotic-therapy, overview] — cited by: wiki/antithrombotic-therapy.md, wiki/overview.md
• Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. PMID 21067804 — tags: [INDEX, STATISTICS, ctt-2010-intensive-ldl, inflammation-and-residual-risk, lipid-lowering, overview, pathophysiology-and-plaque-biology, stable-cad-management] — cited by: INDEX.md, literature/notes/ctt-2010-intensive-ldl.md, literature/statistics/STATISTICS.md, wiki/inflammation-and-residual-risk.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md, wiki/stable-cad-management.md
• Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387-97. PMID 26039521 — tags: [STATISTICS, acute-coronary-syndromes, lipid-lowering, overview, stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/stable-cad-management.md
• Velazquez EJ, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374:1511-20. PMID 27040723 — tags: [INDEX, OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, overview, patient-experience-and-advocacy, revascularization-pci-and-cabg] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md
• Khera AV, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375:2349-2358. PMID 27959714 — tags: [biomarkers, cardiac-rehabilitation-and-lifestyle, epidemiology-and-global-burden, lipid-lowering] — cited by: wiki/biomarkers.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/epidemiology-and-global-burden.md, wiki/lipid-lowering.md
• Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713-1722. PMID 28304224 — tags: [OPEN-QUESTIONS, STATISTICS, biomarkers, clinical-trials-landscape, inflammation-and-residual-risk, lipid-lowering, overview, pathophysiology-and-plaque-biology, stable-cad-management] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/biomarkers.md, wiki/clinical-trials-landscape.md, wiki/inflammation-and-residual-risk.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md, wiki/stable-cad-management.md
• Eikelboom JW, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-1330. PMID 28844192 — tags: [STATISTICS, antithrombotic-therapy, inflammation-and-residual-risk, overview, stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md, wiki/inflammation-and-residual-risk.md, wiki/overview.md, wiki/stable-cad-management.md
• Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-1131. PMID 28845751 — tags: [INDEX, OPEN-QUESTIONS, STATISTICS, biomarkers, clinical-trials-landscape, inflammation-and-residual-risk, overview, pathophysiology-and-plaque-biology, ridker-2017-cantos, stable-cad-management] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/ridker-2017-cantos.md, literature/statistics/STATISTICS.md, wiki/biomarkers.md, wiki/clinical-trials-landscape.md, wiki/inflammation-and-residual-risk.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md, wiki/stable-cad-management.md
• Al-Lamee R, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40. PMID 29103656 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, inoca-and-special-phenotypes, overview, patient-experience-and-advocacy, stable-cad-management] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/stable-cad-management.md
• Ford TJ, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72:2841-2855. PMID 30266608 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, inoca-and-special-phenotypes, overview, patient-experience-and-advocacy, sources, themes] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md
• Landmesser U, et al. Coronary disease prevention: towards a more personalised approach. Eur J Prev Cardiol. 2018;25:1884-1886. PMID 30322267 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. PMID 30415628 — tags: [STATISTICS, lipid-lowering, overview] — cited by: literature/statistics/STATISTICS.md, wiki/lipid-lowering.md, wiki/overview.md
• Tardif JC, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497-2505. PMID 31733140 — tags: [OPEN-QUESTIONS, STATISTICS, acute-coronary-syndromes, clinical-trials-landscape, guidelines, inflammation-and-residual-risk, overview, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inflammation-and-residual-risk.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md
• Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. PMID 32227755 — tags: [INDEX, OPEN-QUESTIONS, STATISTICS, clinical-trials-landscape, guidelines, maron-2020-ischemia, overview, pathophysiology-and-plaque-biology, patient-experience-and-advocacy, revascularization-pci-and-cabg, stable-cad-management] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/notes/maron-2020-ischemia.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Bangalore S, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020;382:1608-1618. PMID 32227756 — tags: [INDEX, STATISTICS, epidemiology-and-global-burden, patient-experience-and-advocacy] — cited by: INDEX.md, literature/statistics/STATISTICS.md, wiki/epidemiology-and-global-burden.md, wiki/patient-experience-and-advocacy.md
• Nidorf SM, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838-1847. PMID 32865380 — tags: [OPEN-QUESTIONS, STATISTICS, clinical-trials-landscape, guidelines, inflammation-and-residual-risk, overview, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inflammation-and-residual-risk.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md
• Aminorroaya A, et al. Global, regional, and national quality of care of ischaemic heart disease from 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017. Eur J Prev Cardiol. 2022;29:371-379. PMID 34041535 — tags: [OPEN-QUESTIONS, STATISTICS, epidemiology-and-global-burden, overview] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/epidemiology-and-global-burden.md, wiki/overview.md
• Dibben G, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11:CD001800. PMID 34741536 — tags: [STATISTICS, cardiac-rehabilitation-and-lifestyle, overview] — cited by: literature/statistics/STATISTICS.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/overview.md
• Bhatt DL, et al. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327:662-675. PMID 35166796 — tags: [acute-coronary-syndromes, epidemiology-and-global-burden, red-flags-and-safety-concerns] — cited by: wiki/acute-coronary-syndromes.md, wiki/epidemiology-and-global-burden.md, wiki/red-flags-and-safety-concerns.md
• Stone NJ, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:819-836. PMID 35210038 — tags: [epidemiology-and-global-burden, lipid-lowering] — cited by: wiki/epidemiology-and-global-burden.md, wiki/lipid-lowering.md
• Castellano JM, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387:967-977. PMID 36018037 — tags: [OPEN-QUESTIONS, STATISTICS, cardiac-rehabilitation-and-lifestyle, clinical-trials-landscape, epidemiology-and-global-burden, lipid-lowering, overview, patient-experience-and-advocacy, sources, stable-cad-management, themes] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/clinical-trials-landscape.md, wiki/epidemiology-and-global-burden.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/stable-cad-management.md
• Perera D, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022;387:1351-1360. PMID 36027563 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, overview, patient-experience-and-advocacy, perera-2022-revived, revascularization-pci-and-cabg] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/perera-2022-revived.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md
• Regitz-Zagrosek V, et al. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat Rev Cardiol. 2023;20:236-247. PMID 36316574 — tags: [epidemiology-and-global-burden, inoca-and-special-phenotypes, patient-experience-and-advocacy] — cited by: wiki/epidemiology-and-global-burden.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md
• Hochman JS, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147:8-19. PMID 36335918 — tags: [OPEN-QUESTIONS, STATISTICS, guidelines, overview, revascularization-pci-and-cabg, stable-cad-management] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/guidelines.md, wiki/overview.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Marston NA, et al. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023;8:130-137. PMID 36576811 — tags: [OPEN-QUESTIONS, biomarkers, epidemiology-and-global-burden] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md, wiki/epidemiology-and-global-burden.md
• Aw PY, et al. Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysis. J Psychosom Res. 2023;165:111141. PMID 36610338 — tags: [cardiac-rehabilitation-and-lifestyle, epidemiology-and-global-burden] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/epidemiology-and-global-burden.md
• Dibben GO, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44:452-469. PMID 36746187 — tags: [OPEN-QUESTIONS, STATISTICS, acute-coronary-syndromes, cardiac-rehabilitation-and-lifestyle, clinical-trials-landscape, epidemiology-and-global-burden, overview, patient-experience-and-advocacy, red-flags-and-safety-concerns, sources, stable-cad-management, themes] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/clinical-trials-landscape.md, wiki/epidemiology-and-global-burden.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md, wiki/stable-cad-management.md
• Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501 — tags: [REGISTRY, antithrombotic-therapy, cardiac-rehabilitation-and-lifestyle, epidemiology-and-global-burden, guidelines, inoca-and-special-phenotypes, lipid-lowering, overview, revascularization-pci-and-cabg, stable-cad-management] — cited by: literature/guidelines/REGISTRY.md, wiki/antithrombotic-therapy.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/epidemiology-and-global-burden.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. PMID 37952131 — tags: [STATISTICS, cardiac-rehabilitation-and-lifestyle, inflammation-and-residual-risk, lipid-lowering, overview, stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/inflammation-and-residual-risk.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/stable-cad-management.md
• Rajkumar CA, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389:2319-2330. PMID 38015442 — tags: [INDEX, OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, inoca-and-special-phenotypes, overview, patient-experience-and-advocacy, rajkumar-2023-orbita2, revascularization-pci-and-cabg, sources, stable-cad-management, themes] — cited by: INDEX.md, OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/notes/rajkumar-2023-orbita2.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Grant E, et al. Ischemic Heart Disease in Women. Med Clin North Am. 2024;108:567-579. PMID 38548464 — tags: [OPEN-QUESTIONS, epidemiology-and-global-burden, inoca-and-special-phenotypes, patient-experience-and-advocacy] — cited by: OPEN-QUESTIONS.md, wiki/epidemiology-and-global-burden.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md
• Foley MJ, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet. 2024;403:1543-1553. PMID 38604209 — tags: [STATISTICS, clinical-trials-landscape, overview, stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/overview.md, wiki/stable-cad-management.md
• Simader FA, et al. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024;84:13-24. PMID 38759906 — tags: [OPEN-QUESTIONS, inoca-and-special-phenotypes, overview, patient-experience-and-advocacy, sources, stable-cad-management, themes] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/inoca-and-special-phenotypes.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/stable-cad-management.md
• Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-3537. PMID 39210710 — tags: [REGISTRY, biomarkers, epidemiology-and-global-burden, guidelines, inoca-and-special-phenotypes, lipid-lowering, overview, revascularization-pci-and-cabg, stable-cad-management] — cited by: literature/guidelines/REGISTRY.md, wiki/biomarkers.md, wiki/epidemiology-and-global-burden.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/lipid-lowering.md, wiki/overview.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Foley MJ, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation. 2025;151:202-214. PMID 39462291 — tags: [OPEN-QUESTIONS, overview, patient-experience-and-advocacy, revascularization-pci-and-cabg, stable-cad-management] — cited by: OPEN-QUESTIONS.md, wiki/overview.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Chong RJ, et al. Prevalence of Depression, Anxiety and Post-Traumatic Stress Disorder (PTSD) After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14. PMID 40142595 — tags: [OPEN-QUESTIONS, cardiac-rehabilitation-and-lifestyle, epidemiology-and-global-burden, inoca-and-special-phenotypes, patient-experience-and-advocacy, sources, themes] — cited by: OPEN-QUESTIONS.md, literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/epidemiology-and-global-burden.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md
• Yang L, et al. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. BMC Cardiovasc Disord. 2025;25:625. PMID 40841929 — tags: [INDEX, STATISTICS, epidemiology-and-global-burden, overview] — cited by: INDEX.md, literature/statistics/STATISTICS.md, wiki/epidemiology-and-global-burden.md, wiki/overview.md
• Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators, et al. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-2243. PMID 40990886 — tags: [STATISTICS, epidemiology-and-global-burden, overview] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-global-burden.md, wiki/overview.md
• GBD 2023 LDL Cholesterol Collaborators, et al. Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023. JAMA. 2026;336:673-698. PMID 42525403 — tags: [biomarkers, epidemiology-and-global-burden, lipid-lowering, overview] — cited by: wiki/biomarkers.md, wiki/epidemiology-and-global-burden.md, wiki/lipid-lowering.md, wiki/overview.md

Plaque biology and biomarkers

• Falk E, et al. Coronary plaque disruption. Circulation. 1995;92:657-71. PMID 7634481 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Conti CR, et al. Finding the vulnerable plaque. Clin Cardiol. 2010;33:320-1. PMID 20556800 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Stone GW, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35. PMID 21247313 — tags: [OPEN-QUESTIONS, STATISTICS, biomarkers, clinical-trials-landscape, inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/biomarkers.md, wiki/clinical-trials-landscape.md, wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Papadopoulou SL, et al. Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging. 2012;5:S28-37. PMID 22421228 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Braunwald E, et al. Coronary plaque erosion: recognition and management. JACC Cardiovasc Imaging. 2013;6:288-9. PMID 23473110 — tags: [OPEN-QUESTIONS, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/pathophysiology-and-plaque-biology.md
• Park KC, et al. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113:1708-1718. PMID 29016754 — tags: [biomarkers, inoca-and-special-phenotypes, red-flags-and-safety-concerns] — cited by: wiki/biomarkers.md, wiki/inoca-and-special-phenotypes.md, wiki/red-flags-and-safety-concerns.md
• Schwartz GG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-2107. PMID 30403574 — tags: [STATISTICS, biomarkers, inflammation-and-residual-risk, lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/biomarkers.md, wiki/inflammation-and-residual-risk.md, wiki/lipid-lowering.md
• Ridker PM, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380:752-762. PMID 30415610 — tags: [biomarkers, clinical-trials-landscape, inflammation-and-residual-risk, overview, pathophysiology-and-plaque-biology] — cited by: wiki/biomarkers.md, wiki/clinical-trials-landscape.md, wiki/inflammation-and-residual-risk.md, wiki/overview.md, wiki/pathophysiology-and-plaque-biology.md
• Wang X, et al. A zero coronary artery calcium score in patients with stable chest pain is associated with a good prognosis, despite risk of non-calcified plaques. Open Heart. 2019;6:e000945. PMID 31168373 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Williams MC, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020;141:1452-1462. PMID 32174130 — tags: [OPEN-QUESTIONS, biomarkers, inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md, wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Chuang AM, et al. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond. Rev Cardiovasc Med. 2020;21:191-203. PMID 32706208 — tags: [biomarkers, red-flags-and-safety-concerns] — cited by: wiki/biomarkers.md, wiki/red-flags-and-safety-concerns.md
• Ajala ON, et al. Targeting Inflammation to Reduce Residual Cardiovascular Risk. Curr Atheroscler Rep. 2020;22:66. PMID 32880743 — tags: [inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Samuel M, et al. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). Future Cardiol. 2021;17:411-414. PMID 33687270 — tags: [inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Klarin D, et al. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022;19:291-301. PMID 34811547 — tags: [OPEN-QUESTIONS, biomarkers] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md
• Koopman MY, et al. The Diagnostic and Prognostic Value of Coronary Calcium Scoring in Stable Chest Pain Patients: A Narrative Review. Rofo. 2022;194:257-265. PMID 35081649 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Chowdhury RR, et al. Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self. Circ Res. 2022;130:1510-1530. PMID 35430876 — tags: [OPEN-QUESTIONS, inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Ahn JM, et al. Preventive PCI or medical therapy alone for vulnerable atherosclerotic coronary plaque: Rationale and design of the randomized, controlled PREVENT trial. Am Heart J. 2023;264:83-96. PMID 37271356 — tags: [OPEN-QUESTIONS, biomarkers, clinical-trials-landscape, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md, wiki/clinical-trials-landscape.md, wiki/pathophysiology-and-plaque-biology.md
• Wereski R, et al. High-Sensitivity Cardiac Troponin for Risk Assessment in Patients With Chronic Coronary Artery Disease. J Am Coll Cardiol. 2023;82:473-485. PMID 37532417 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Maclean E, et al. Prognostic utility of semi-quantitative coronary computed tomography angiography scores in the SCOT-HEART trial. J Cardiovasc Comput Tomogr. 2023;17:393-400. PMID 37673712 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Koo BK, et al. Artificial Intelligence-Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome. JACC Cardiovasc Imaging. 2024;17:1062-1076. PMID 38752951 — tags: [OPEN-QUESTIONS, biomarkers, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md, wiki/pathophysiology-and-plaque-biology.md
• Ueki Y, et al. Lipid-lowering Therapy and Coronary Plaque Regression. J Atheroscler Thromb. 2024;31:1479-1495. PMID 39111840 — tags: [inflammation-and-residual-risk, lipid-lowering, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/lipid-lowering.md, wiki/pathophysiology-and-plaque-biology.md
• Yu M, et al. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial. Circulation. 2024;150:981-993. PMID 39166327 — tags: [OPEN-QUESTIONS, inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Fiolet ATL, et al. Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. Heart. 2025;111:1156-1163. PMID 40393691 — tags: [OPEN-QUESTIONS, inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: OPEN-QUESTIONS.md, wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Kim MC, et al. Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial. Eur Heart J. 2025;46:3181-3197. PMID 40439104 — tags: [clinical-trials-landscape, pathophysiology-and-plaque-biology] — cited by: wiki/clinical-trials-landscape.md, wiki/pathophysiology-and-plaque-biology.md

Stable disease and revascularization

• Stone GW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016;375:2223-2235. PMID 27797291 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Berry C, et al. Meta-Analysis of Death and Myocardial Infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. Circulation. 2017;136:2389-2391. PMID 28972006 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Head SJ, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391:939-948. PMID 29478841 — tags: [guidelines, revascularization-pci-and-cabg] — cited by: wiki/guidelines.md, wiki/revascularization-pci-and-cabg.md
• Mehta SR, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381:1411-1421. PMID 31475795 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, acute-coronary-syndromes, revascularization-pci-and-cabg] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/revascularization-pci-and-cabg.md
• Thuijs DJFM, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325-1334. PMID 31488373 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Azzalini L, et al. Percutaneous Coronary Intervention or Surgery for Unprotected Left Main Disease: EXCEL Trial at 5 Years. Interv Cardiol Clin. 2020;9:419-432. PMID 32921366 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Teoh Z, et al. COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Interv Cardiol Clin. 2020;9:469-482. PMID 32921371 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Joshi PH, et al. Diagnosis and Management of Stable Angina: A Review. JAMA. 2021;325:1765-1778. PMID 33944871 — tags: [inoca-and-special-phenotypes, red-flags-and-safety-concerns, stable-cad-management] — cited by: wiki/inoca-and-special-phenotypes.md, wiki/red-flags-and-safety-concerns.md, wiki/stable-cad-management.md
• Brown DL, et al. Optimal Medical Therapy as First-Line Therapy for Chronic Coronary Syndromes: Lessons from COURAGE, BARI 2D, FAME 2, and ISCHEMIA. Cardiovasc Drugs Ther. 2022;36:1039-1045. PMID 34767134 — tags: [revascularization-pci-and-cabg, stable-cad-management] — cited by: wiki/revascularization-pci-and-cabg.md, wiki/stable-cad-management.md
• Sabatine MS, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398:2247-2257. PMID 34793745 — tags: [guidelines, revascularization-pci-and-cabg] — cited by: wiki/guidelines.md, wiki/revascularization-pci-and-cabg.md
• Rashid M, et al. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials. J Am Heart Assoc. 2022;11:e025426. PMID 36102261 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Weintraub WS, et al. Percutaneous coronary intervention from COURAGE to ISCHEMIA and beyond. Int J Cardiol. 2023;373:39-43. PMID 36427605 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Byrne RA, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg. 2023;64. PMID 37632766 — tags: [REGISTRY, guidelines, overview, revascularization-pci-and-cabg] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/overview.md, wiki/revascularization-pci-and-cabg.md
• Eftekhari A, et al. Instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART and DEFINE FLAIR. Eur Heart J. 2023;44:4376-4384. PMID 37634144 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Stähli BE, et al. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2023;389:1368-1379. PMID 37634190 — tags: [OPEN-QUESTIONS, REGISTRY, acute-coronary-syndromes, revascularization-pci-and-cabg] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, wiki/acute-coronary-syndromes.md, wiki/revascularization-pci-and-cabg.md
• Ahmed-Jushuf F, et al. Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial. J Am Coll Cardiol. 2025;85:1740-1753. PMID 40335250 — tags: [OPEN-QUESTIONS, stable-cad-management] — cited by: OPEN-QUESTIONS.md, wiki/stable-cad-management.md

Acute coronary syndromes and antithrombotics

• Dalby M, et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-14. PMID 14530206 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166. PMID 25399658 — tags: [OPEN-QUESTIONS, antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, wiki/antithrombotic-therapy.md
• Engstrøm T, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665-71. PMID 26347918 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Manfrini O, et al. Early Invasive Strategy for Unstable Angina: a New Meta-Analysis of Old Clinical Trials. Sci Rep. 2016;6:27345. PMID 27273697 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• George B, et al. Revascularization Strategies for Non-ST-Elevation Myocardial Infarction. Curr Cardiol Rep. 2019;21:39. PMID 30969393 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Vogel B, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5:39. PMID 31171787 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Ferry AV, et al. Presenting Symptoms in Men and Women Diagnosed With Myocardial Infarction Using Sex-Specific Criteria. J Am Heart Assoc. 2019;8:e012307. PMID 31431112 — tags: [OPEN-QUESTIONS, STATISTICS, acute-coronary-syndromes, inoca-and-special-phenotypes, patient-experience-and-advocacy, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• Mehran R, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381:2032-2042. PMID 31556978 — tags: [OPEN-QUESTIONS, STATISTICS, antithrombotic-therapy, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md, wiki/red-flags-and-safety-concerns.md
• Dangas G, et al. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020;75:2414-2424. PMID 32240761 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• van Oosterhout REM, et al. Sex Differences in Symptom Presentation in Acute Coronary Syndromes: A Systematic Review and Meta-analysis. J Am Heart Assoc. 2020;9:e014733. PMID 32363989 — tags: [acute-coronary-syndromes, inoca-and-special-phenotypes, patient-experience-and-advocacy, red-flags-and-safety-concerns, sources, themes] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/acute-coronary-syndromes.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• Chew DP, et al. Mortality From Bleeding Versus Myocardial Infarction: Loosening A Strand of the Antithrombotic Therapy "Gordian Knot". J Am Coll Cardiol. 2020;76:172-174. PMID 32646566 — tags: [acute-coronary-syndromes, antithrombotic-therapy, clinical-trials-landscape, red-flags-and-safety-concerns] — cited by: wiki/acute-coronary-syndromes.md, wiki/antithrombotic-therapy.md, wiki/clinical-trials-landscape.md, wiki/red-flags-and-safety-concerns.md
• Collet JP, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367. PMID 32860058 — tags: [REGISTRY, acute-coronary-syndromes] — cited by: literature/guidelines/REGISTRY.md, wiki/acute-coronary-syndromes.md
• White HD, et al. Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction? J Am Heart Assoc. 2021;10:e019796. PMID 33372537 — tags: [OPEN-QUESTIONS, acute-coronary-syndromes, inoca-and-special-phenotypes, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, wiki/acute-coronary-syndromes.md, wiki/inoca-and-special-phenotypes.md, wiki/red-flags-and-safety-concerns.md
• Valgimigli M, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021;385:1643-1655. PMID 34449185 — tags: [OPEN-QUESTIONS, STATISTICS, antithrombotic-therapy, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md, wiki/red-flags-and-safety-concerns.md
• Chiarito M, et al. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022;15:282-293. PMID 35033468 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-3826. PMID 37622654 — tags: [REGISTRY, STATISTICS, acute-coronary-syndromes, antithrombotic-therapy, guidelines, red-flags-and-safety-concerns] — cited by: literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/antithrombotic-therapy.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md
• Fong KY, et al. Role of Invasive Strategy for Non-ST-Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Am J Cardiol. 2023;205:369-378. PMID 37639763 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Yndigegn T, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390:1372-1381. PMID 38587241 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, acute-coronary-syndromes, guidelines, overview] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/guidelines.md, wiki/overview.md
• Silvain J, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024;391:1277-1286. PMID 39213187 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, acute-coronary-syndromes, guidelines] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/guidelines.md
• Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-e862. PMID 40014670 — tags: [REGISTRY, STATISTICS, acute-coronary-syndromes, antithrombotic-therapy, guidelines, red-flags-and-safety-concerns] — cited by: literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/antithrombotic-therapy.md, wiki/guidelines.md, wiki/red-flags-and-safety-concerns.md

Lipids and inflammation

• Ray KK, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382:1507-1519. PMID 32187462 — tags: [STATISTICS, clinical-trials-landscape, lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/lipid-lowering.md
• Howard JP, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021;78:1210-1222. PMID 34531021 — tags: [lipid-lowering, red-flags-and-safety-concerns] — cited by: wiki/lipid-lowering.md, wiki/red-flags-and-safety-concerns.md
• Krishnamurthy A, et al. SAMSON and the Nocebo Effect: Management of Statin Intolerance. Curr Cardiol Rep. 2022;24:1101-1108. PMID 35759168 — tags: [lipid-lowering] — cited by: wiki/lipid-lowering.md
• Nissen SE, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388:1353-1364. PMID 36876740 — tags: [STATISTICS, clinical-trials-landscape, lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/lipid-lowering.md
• Wada Y, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82:279-285. PMID 37211246 — tags: [OPEN-QUESTIONS, inflammation-and-residual-risk] — cited by: OPEN-QUESTIONS.md, wiki/inflammation-and-residual-risk.md
• Jolly SS, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2025;392:633-642. PMID 39555823 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, clinical-trials-landscape, guidelines, inflammation-and-residual-risk] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inflammation-and-residual-risk.md

Rehabilitation and patient experience

• Anderson L, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016;67:1-12. PMID 26764059 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Richards SH, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:247-259. PMID 29212370 — tags: [OPEN-QUESTIONS, cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy] — cited by: OPEN-QUESTIONS.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md
• Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378:e34. PMID 29897866 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Kunadian V, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41:3504-3520. PMID 32626906 — tags: [OPEN-QUESTIONS, guidelines, inoca-and-special-phenotypes, patient-experience-and-advocacy, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• Chang JT, et al. Cigarette Smoking Reduction and Health Risks: A Systematic Review and Meta-analysis. Nicotine Tob Res. 2021;23:635-642. PMID 32803250 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Bäck M, et al. Perceptions of Kinesiophobia in Relation to Physical Activity and Exercise After Myocardial Infarction: A Qualitative Study. Phys Ther. 2020;100:2110-2119. PMID 32886775 — tags: [cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy, red-flags-and-safety-concerns, sources, themes] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md, wiki/red-flags-and-safety-concerns.md
• Deka P, et al. High-Intensity Interval and Resistance Training Improve Health Outcomes in Older Adults With Coronary Disease. J Am Med Dir Assoc. 2022;23:60-65. PMID 34171293 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Xie X, et al. Barriers to hospital-based phase 2 cardiac rehabilitation among patients with coronary heart disease in China: a mixed-methods study. BMC Nurs. 2022;21:333. PMID 36447215 — tags: [cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy, sources, themes] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md
• Borah N, et al. Challenges to Cardiac Rehabilitation Post Coronary Artery Bypass Grafting: A Qualitative Study in Pune. Cureus. 2023;15:e35755. PMID 37033594 — tags: [cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy, sources, themes] — cited by: literature/patient-voice/sources.md, literature/patient-voice/themes.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md
• McDonagh ST, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023;10:CD007130. PMID 37888805 — tags: [OPEN-QUESTIONS, STATISTICS, cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md
• Levine GN, et al. Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association. Circulation. 2025;152:e298-e310. PMID 40977387 — tags: [cardiac-rehabilitation-and-lifestyle, patient-experience-and-advocacy] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/patient-experience-and-advocacy.md

INOCA and special phenotypes

• Beltrame JF, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565-2568. PMID 26245334 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Ong P, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20. PMID 29031990 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Brainin P, et al. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: A systematic review and meta-analysis. Int J Cardiol. 2018;254:1-9. PMID 29407076 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Kelshiker MA, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43:1582-1593. PMID 34849697 — tags: [OPEN-QUESTIONS, clinical-trials-landscape, guidelines, inoca-and-special-phenotypes, overview, red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md, wiki/overview.md, wiki/red-flags-and-safety-concerns.md
• Parwani P, et al. Contemporary Diagnosis and Management of Patients with MINOCA. Curr Cardiol Rep. 2023;25:561-570. PMID 37067753 — tags: [inoca-and-special-phenotypes, red-flags-and-safety-concerns] — cited by: wiki/inoca-and-special-phenotypes.md, wiki/red-flags-and-safety-concerns.md
• Kei CY, et al. Coronary "Microvascular Dysfunction": Evolving Understanding of Pathophysiology, Clinical Implications, and Potential Therapeutics. Int J Mol Sci. 2023;24. PMID 37511046 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Jenkins K, et al. Vasospastic angina: a review on diagnostic approach and management. Ther Adv Cardiovasc Dis. 2024;18:17539447241230400. PMID 38343041 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md

Guidelines, trials, and safety

• Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188. PMID 31504418 — tags: [REGISTRY, guidelines, lipid-lowering] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/lipid-lowering.md
• Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. PMID 34458905 — tags: [REGISTRY, cardiac-rehabilitation-and-lifestyle, epidemiology-and-global-burden, guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/cardiac-rehabilitation-and-lifestyle.md, wiki/epidemiology-and-global-burden.md, wiki/guidelines.md
• Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144:e368-e454. PMID 34709879 — tags: [REGISTRY, biomarkers, guidelines, inoca-and-special-phenotypes] — cited by: literature/guidelines/REGISTRY.md, wiki/biomarkers.md, wiki/guidelines.md, wiki/inoca-and-special-phenotypes.md
• Writing Committee Members, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21-e129. PMID 34895950 — tags: [REGISTRY, guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479. PMID 40885687 — tags: [REGISTRY, guidelines, lipid-lowering] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md, wiki/lipid-lowering.md
• Brieger DB, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025. Med J Aust. 2026;224:e70127. PMID 41693087 — tags: [REGISTRY] — cited by: literature/guidelines/REGISTRY.md

Deepening additions — 2026-08-30

Every record below was resolved through live PubMed E-utilities during the deepening session.

Additional epidemiology and burden evidence

• Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. PMID 15364185 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Arora S, et al. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation. 2019;139:1047-1056. PMID 30586725 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Yusuf S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795-808. PMID 31492503 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Rehman H, et al. Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts. Indian Heart J. 2020;72:337-344. PMID 33189191 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• GBD 2021 Causes of Death Collaborators, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100-2132. PMID 38582094 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• GBD 2021 Diseases and Injuries Collaborators, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133-2161. PMID 38642570 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md

Additional acute-syndrome and antithrombotic evidence

• CAPRIE Steering Committee, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-39. PMID 8918275 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. PMID 11519503 — tags: [STATISTICS, antithrombotic-therapy] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15. PMID 17982182 — tags: [STATISTICS, antithrombotic-therapy, red-flags-and-safety-concerns] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md, wiki/red-flags-and-safety-concerns.md
• Fosbøl EL, et al. Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy. Am Heart J. 2008;156:391-6. PMID 18657676 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. PMID 19717846 — tags: [STATISTICS, antithrombotic-therapy, red-flags-and-safety-concerns] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md, wiki/red-flags-and-safety-concerns.md
• Dewilde WJ, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-15. PMID 23415013 — tags: [STATISTICS, antithrombotic-therapy] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Bonaca MP, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. PMID 25773268 — tags: [STATISTICS, antithrombotic-therapy] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Milosevic A, et al. Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study. JACC Cardiovasc Interv. 2016;9:541-9. PMID 26777321 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Gibson CM, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423-2434. PMID 27959713 — tags: [STATISTICS, antithrombotic-therapy] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Cannon CP, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513-1524. PMID 28844193 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Thiele H, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377:2419-2432. PMID 29083953 — tags: [REGISTRY, STATISTICS, acute-coronary-syndromes, red-flags-and-safety-concerns, revascularization-pci-and-cabg] — cited by: literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md, wiki/red-flags-and-safety-concerns.md, wiki/revascularization-pci-and-cabg.md
• Vranckx P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940-949. PMID 30166073 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• Lopes RD, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524. PMID 30883055 — tags: [OPEN-QUESTIONS, REGISTRY, STATISTICS, antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Watanabe H, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321:2414-2427. PMID 31237644 — tags: [OPEN-QUESTIONS, STATISTICS, antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Hahn JY, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321:2428-2437. PMID 31237645 — tags: [OPEN-QUESTIONS, STATISTICS, antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Vranckx P, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335-1343. PMID 31492505 — tags: [REGISTRY, STATISTICS, antithrombotic-therapy] — cited by: literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Koo BK, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487-2496. PMID 34010616 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• Van de Werf F, et al. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial. Circulation. 2023;148:753-764. PMID 37439219 — tags: [STATISTICS, acute-coronary-syndromes] — cited by: literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md

Additional stable-disease and revascularization evidence

• Stone PH, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566-75. PMID 16875985 — tags: [STATISTICS, stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/stable-cad-management.md
• Abdallah MS, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310:1581-90. PMID 24129463 — tags: [STATISTICS, guidelines, patient-experience-and-advocacy, revascularization-pci-and-cabg] — cited by: literature/statistics/STATISTICS.md, wiki/guidelines.md, wiki/patient-experience-and-advocacy.md, wiki/revascularization-pci-and-cabg.md
• Petrie MC, et al. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134:1314-1324. PMID 27573034 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Stone GW, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019;381:1820-1830. PMID 31562798 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Perera D, et al. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023;8:1154-1161. PMID 37878295 — tags: [REGISTRY, STATISTICS, clinical-trials-landscape, revascularization-pci-and-cabg] — cited by: literature/guidelines/REGISTRY.md, literature/statistics/STATISTICS.md, wiki/clinical-trials-landscape.md, wiki/revascularization-pci-and-cabg.md

Additional lipid-lowering evidence

• Anonymous, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. PMID 7968073 — tags: [STATISTICS, lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/lipid-lowering.md
• Heart Protection Study Collaborative Group, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. PMID 12114036 — tags: [lipid-lowering] — cited by: wiki/lipid-lowering.md
• LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. PMID 15755765 — tags: [STATISTICS, lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/lipid-lowering.md
• Burgess S, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018;3:619-627. PMID 29926099 — tags: [biomarkers, lipid-lowering] — cited by: wiki/biomarkers.md, wiki/lipid-lowering.md
• Newman CB, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38-e81. PMID 30580575 — tags: [lipid-lowering, red-flags-and-safety-concerns] — cited by: wiki/lipid-lowering.md, wiki/red-flags-and-safety-concerns.md
• Bhatia HS, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025;151:312-321. PMID 39492722 — tags: [biomarkers, lipid-lowering] — cited by: wiki/biomarkers.md, wiki/lipid-lowering.md

Additional plaque, biomarker, and inflammation evidence

• Ross R, et al. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-26. PMID 9887164 — tags: [inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Libby P, et al. Inflammation in atherosclerosis. Nature. 2002;420:868-74. PMID 12490960 — tags: [inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md
• Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214-24. PMID 22421340 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md
• McClelland RL, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643-53. PMID 26449133 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Burgos LM, et al. Performance of the European Society of Cardiology 0/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin: Systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2021;10:279–286. PMID 32597681 — tags: [biomarkers, red-flags-and-safety-concerns] — cited by: wiki/biomarkers.md, wiki/red-flags-and-safety-concerns.md
• Anand A, et al. High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation. 2021;143:2214-2224. PMID 33752439 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Ridker PM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:2060-2069. PMID 34015342 — tags: [OPEN-QUESTIONS, clinical-trials-landscape, inflammation-and-residual-risk] — cited by: OPEN-QUESTIONS.md, wiki/clinical-trials-landscape.md, wiki/inflammation-and-residual-risk.md
• Marnell CS, et al. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98-105. PMID 34298011 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md
• Zuriaga MA, et al. Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. Clin Investig Arterioscler. 2023;35:35-41. PMID 34879980 — tags: [inflammation-and-residual-risk, pathophysiology-and-plaque-biology] — cited by: wiki/inflammation-and-residual-risk.md, wiki/pathophysiology-and-plaque-biology.md

Additional INOCA and diagnostic-safety evidence

• Backus BE, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol. 2013;168:2153-8. PMID 23465250 — tags: [red-flags-and-safety-concerns] — cited by: wiki/red-flags-and-safety-concerns.md
• Chiang CH, et al. Safety and efficacy of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial infarction: systematic review and meta-analysis. Heart. 2020;106:985-991. PMID 32245882 — tags: [red-flags-and-safety-concerns] — cited by: wiki/red-flags-and-safety-concerns.md
• Bryniarski K, et al. OCT Findings in MINOCA. J Clin Med. 2021;10:2759. PMID 34201727 — tags: [inoca-and-special-phenotypes, red-flags-and-safety-concerns] — cited by: wiki/inoca-and-special-phenotypes.md, wiki/red-flags-and-safety-concerns.md
• Jansen TPJ, et al. Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA: The EDIT-CMD Randomized Clinical Trial. JACC Cardiovasc Imaging. 2022;15:1473-1484. PMID 35466050 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md

Additional rehabilitation and patient-experience evidence

• Mendes de Leon CF, et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial. J Cardiopulm Rehabil. 2006;26:9-13; quiz 14-5. PMID 16617220 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Doherty P, et al. The RAMIT trial, a pragmatic RCT of cardiac rehabilitation versus usual care: what does it tell us? Heart. 2012;98:605-6. PMID 22505460 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Sun EY, et al. Disparities in Cardiac Rehabilitation Participation in the United States: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2017;37:2-10. PMID 27676464 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Rees K, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019;3:CD009825. PMID 30864165 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Ramachandran HJ, et al. Effectiveness of home-based cardiac telerehabilitation as an alternative to Phase 2 cardiac rehabilitation of coronary heart disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:1017-1043. PMID 34254118 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Wu AD, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022;8:CD014936. PMID 35938889 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md

Topic-specific evidence expansion — 2026-09-02

Acute coronary syndromes

• Vranckx P, et al. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. European heart journal. 2017;38:1069-1080. PMID 28329389 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md
• Thiele H, et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. The New England journal of medicine. 2023;389:1286-1297. PMID 37634145 — tags: [acute-coronary-syndromes] — cited by: OPEN-QUESTIONS.md, literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md
• Hofmann R, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. The New England journal of medicine. 2017;377:1240-1249. PMID 28844200 — tags: [acute-coronary-syndromes] — cited by: literature/statistics/STATISTICS.md, wiki/acute-coronary-syndromes.md
• Sanchis J, et al. Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial. Heart (British Cardiac Society). 2025;111:786-792. PMID 39922692 — tags: [acute-coronary-syndromes] — cited by: wiki/acute-coronary-syndromes.md

Antithrombotic therapy

• Kang J, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2023;147:108-117. PMID 36342475 — tags: [antithrombotic-therapy] — cited by: literature/statistics/STATISTICS.md, wiki/antithrombotic-therapy.md
• Kim BK, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020;323:2407-2416. PMID 32543684 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md
• Murphy SA, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European heart journal. 2008;29:2473-9. PMID 18682445 — tags: [antithrombotic-therapy] — cited by: OPEN-QUESTIONS.md, wiki/antithrombotic-therapy.md
• Gimbel M, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet (London, England). 2020;395:1374-1381. PMID 32334703 — tags: [antithrombotic-therapy] — cited by: wiki/antithrombotic-therapy.md

Biomarkers and imaging

• Reichlin T, et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2015;187:E243-E252. PMID 25869867 — tags: [biomarkers] — cited by: literature/statistics/STATISTICS.md, wiki/biomarkers.md
• Lee KK, et al. Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome. Journal of the American College of Cardiology. 2019;74:2032-2043. PMID 31623760 — tags: [biomarkers] — cited by: OPEN-QUESTIONS.md, wiki/biomarkers.md
• Martin SS, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129:77-86. PMID 24141324 — tags: [biomarkers] — cited by: wiki/biomarkers.md
• Williams MC, et al. Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study. Journal of the American College of Cardiology. 2019;73:291-301. PMID 30678759 — tags: [biomarkers] — cited by: wiki/biomarkers.md

Cardiac rehabilitation and lifestyle

• Grace SL, et al. Automatic referral to cardiac rehabilitation. Medical care. 2004;42:661-9. PMID 15213491 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• Wilson K, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Archives of internal medicine. 2000;160:939-44. PMID 10761958 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: literature/statistics/STATISTICS.md, wiki/cardiac-rehabilitation-and-lifestyle.md
• de Lorgeril M, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779-85. PMID 9989963 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md
• McGregor G, et al. High-intensity interval training in cardiac rehabilitation: a multi-centre randomized controlled trial. European journal of preventive cardiology. 2023;30:745-755. PMID 36753063 — tags: [cardiac-rehabilitation-and-lifestyle] — cited by: wiki/cardiac-rehabilitation-and-lifestyle.md

Clinical-trial methods

• Vranckx P, et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European heart journal. 2014;35:2524-9. PMID 24755007 — tags: [clinical-trials-landscape] — cited by: wiki/clinical-trials-landscape.md
• Gong IY, et al. Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. The Canadian journal of cardiology. 2019;35:653-660. PMID 31030866 — tags: [clinical-trials-landscape] — cited by: wiki/clinical-trials-landscape.md
• Sheikh H, et al. Temporal Trends of Enrollment by Sex and Race in Major Cardiovascular Randomized Clinical Trials. CJC open. 2024;6:454-462. PMID 38487060 — tags: [clinical-trials-landscape] — cited by: wiki/clinical-trials-landscape.md
• Duncan A, et al. Analysis of core outcome set reporting in coronary intervention trials. Open heart. 2024;11:. PMID 38688715 — tags: [clinical-trials-landscape] — cited by: wiki/clinical-trials-landscape.md

Epidemiology and burden

• Tan SCW, et al. Global Burden of Cardiovascular Diseases and its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. QJM : monthly journal of the Association of Physicians. 2025;118:411-422. PMID 39847534 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Schröder SL, et al. Socioeconomic inequalities in access to treatment for coronary heart disease: A systematic review. International journal of cardiology. 2016;219:70-8. PMID 27288969 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Cohen AJ, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet (London, England). 2017;389:1907-1918. PMID 28408086 — tags: [epidemiology-and-global-burden] — cited by: wiki/epidemiology-and-global-burden.md
• Sun J, et al. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries/territories, 1990-2019: a systematic analysis of Global Burden of Disease Study 2019. BMC medicine. 2023;21:222. PMID 37365627 — tags: [epidemiology-and-global-burden] — cited by: literature/statistics/STATISTICS.md, wiki/epidemiology-and-global-burden.md

Guidelines and implementation

• Byrne RA, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European heart journal. 2023;44:4310-4320. PMID 37632756 — tags: [guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Ades PA, et al. Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clinic proceedings. 2017;92:234-242. PMID 27855953 — tags: [guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Ohm J, et al. Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction. JAMA network open. 2021;4:e211129. PMID 33688966 — tags: [guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md
• Valgimigli M, et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024;150:317-335. PMID 39038086 — tags: [guidelines] — cited by: literature/guidelines/REGISTRY.md, wiki/guidelines.md

Inflammation and residual risk

• Gumuser ED, et al. Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 2023;81:1996-2009. PMID 37197843 — tags: [inflammation-and-residual-risk] — cited by: literature/statistics/STATISTICS.md, wiki/inflammation-and-residual-risk.md
• Bohula EA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138:131-140. PMID 29530884 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md
• Ridker PM, et al. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2024;149:28-35. PMID 37929602 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md
• Ballacci F, et al. Colchicine for prevention of major adverse cardiovascular events: a meta-analysis of randomized clinical trials. Journal of cardiovascular medicine (Hagerstown, Md.). 2025;26:359-368. PMID 40530569 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md

INOCA and special phenotypes

• Anderson RD, et al. Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD). Journal of interventional cardiology. 2019;2019:7169275. PMID 31772544 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Opolski MP, et al. Mechanisms of Myocardial Infarction in Patients With Nonobstructive Coronary Artery Disease: Results From the Optical Coherence Tomography Study. JACC. Cardiovascular imaging. 2019;12:2210-2221. PMID 30343070 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Bairey Merz CN, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European heart journal. 2016;37:1504-13. PMID 26614823 — tags: [inoca-and-special-phenotypes] — cited by: wiki/inoca-and-special-phenotypes.md
• Lindahl B, et al. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation. 2017;135:1481-1489. PMID 28179398 — tags: [inoca-and-special-phenotypes] — cited by: literature/statistics/STATISTICS.md, wiki/inoca-and-special-phenotypes.md

Lipid lowering

• Steg PG, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019;140:103-112. PMID 31117810 — tags: [lipid-lowering] — cited by: wiki/lipid-lowering.md
• Nicholls SJ, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA cardiology. 2024;9:245-253. PMID 38231501 — tags: [lipid-lowering] — cited by: OPEN-QUESTIONS.md, wiki/lipid-lowering.md
• Wright RS, et al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Journal of the American College of Cardiology. 2021;77:1182-1193. PMID 33663735 — tags: [lipid-lowering] — cited by: literature/statistics/STATISTICS.md, wiki/lipid-lowering.md
• Leebmann J, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567-76. PMID 24056686 — tags: [lipid-lowering] — cited by: wiki/lipid-lowering.md

Overview and lifetime risk

• Lloyd-Jones DM, et al. Lifetime risk of developing coronary heart disease. Lancet (London, England). 1999;353:89-92. PMID 10023892 — tags: [overview] — cited by: wiki/overview.md
• Zhang Y, et al. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA cardiology. 2021;6:1406-1413. PMID 34550307 — tags: [overview] — cited by: OPEN-QUESTIONS.md, wiki/overview.md
• Kumar A, et al. Revascularization or Optimal Medical Therapy for Stable Ischemic Heart Disease: A Bayesian Meta-Analysis of Contemporary Trials. Cardiovascular revascularization medicine : including molecular interventions. 2022;40:42-47. PMID 35210188 — tags: [overview] — cited by: wiki/overview.md
• Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet (London, England). 2019;394:672-683. PMID 31448738 — tags: [overview] — cited by: wiki/overview.md

Plaque biology and mechanism

• Williams KJ, et al. The response-to-retention hypothesis of atherogenesis reinforced. Current opinion in lipidology. 1998;9:471-4. PMID 9812202 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Cai B, et al. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. The Journal of clinical investigation. 2017;127:564-568. PMID 28067670 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Shankman LS, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nature medicine. 2015;21:628-37. PMID 25985364 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md
• Dong Z, et al. Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis. European heart journal. 2024;45:669-684. PMID 38085922 — tags: [pathophysiology-and-plaque-biology] — cited by: wiki/pathophysiology-and-plaque-biology.md

Patient experience

• Shafiq A, et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. American heart journal. 2016;175:94-100. PMID 27179728 — tags: [patient-experience-and-advocacy] — cited by: wiki/patient-experience-and-advocacy.md
• Coylewright M, et al. Shared decision making in patients with stable coronary artery disease: PCI choice. PloS one. 2012;7:e49827. PMID 23226223 — tags: [patient-experience-and-advocacy] — cited by: wiki/patient-experience-and-advocacy.md
• Kai SHY, et al. Prevalence and determinants of return to work after various coronary events: meta-analysis of prospective studies. Scientific reports. 2022;12:15348. PMID 36097026 — tags: [patient-experience-and-advocacy] — cited by: literature/statistics/STATISTICS.md, wiki/patient-experience-and-advocacy.md
• Abramsohn EM, et al. "I'm not just a heart, I'm a whole person here": a qualitative study to improve sexual outcomes in women with myocardial infarction. Journal of the American Heart Association. 2013;2:e000199. PMID 23885024 — tags: [patient-experience-and-advocacy] — cited by: wiki/patient-experience-and-advocacy.md

Red flags and safety

• Pope JH, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. The New England journal of medicine. 2000;342:1163-70. PMID 10770981 — tags: [red-flags-and-safety-concerns] — cited by: literature/statistics/STATISTICS.md, wiki/red-flags-and-safety-concerns.md
• McClure JD, et al. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American Heart Association. 2020;9:e017109. PMID 32779497 — tags: [red-flags-and-safety-concerns] — cited by: wiki/red-flags-and-safety-concerns.md
• Jović Z, et al. Does thrombolytic therapy harm or help in ST elevation myocardial infarction (STEMI) caused by the spontaneous coronary dissection? Vojnosanitetski pregled. 2015;72:536-40. PMID 26226727 — tags: [red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, wiki/red-flags-and-safety-concerns.md
• Saaby L, et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. The American journal of medicine. 2014;127:295-302. PMID 24457000 — tags: [red-flags-and-safety-concerns] — cited by: wiki/red-flags-and-safety-concerns.md

Revascularization

• Xaplanteris P, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. The New England journal of medicine. 2018;379:250-259. PMID 29785878 — tags: [revascularization-pci-and-cabg] — cited by: literature/statistics/STATISTICS.md, wiki/revascularization-pci-and-cabg.md
• Serruys PW, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. The New England journal of medicine. 2009;360:961-72. PMID 19228612 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Akintoye E, et al. Intermediate and Late Outcomes With PCI vs CABG for Left Main Disease - Landmark Meta-Analysis of Randomized Trials. Cardiovascular revascularization medicine : including molecular interventions. 2021;23:114-118. PMID 32921597 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md
• Spertus JA, et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. The New England journal of medicine. 2020;382:1408-1419. PMID 32227753 — tags: [revascularization-pci-and-cabg] — cited by: wiki/revascularization-pci-and-cabg.md

Stable coronary disease

• Hueb W, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010;122:949-57. PMID 20733102 — tags: [stable-cad-management] — cited by: literature/statistics/STATISTICS.md, wiki/stable-cad-management.md
• Mark DB, et al. Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. Circulation. 2022;145:1294-1307. PMID 35259918 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Wenger NK, et al. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. The American journal of cardiology. 2007;99:11-8. PMID 17196454 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-9. PMID 23032550 — tags: [stable-cad-management] — cited by: wiki/stable-cad-management.md
• Hayes SN, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137:e523-e557. PMID 29472380 — tags: [red-flags-and-safety-concerns] — cited by: OPEN-QUESTIONS.md, wiki/red-flags-and-safety-concerns.md

Independent-audit additions — 2026-09-02

Records added by the audit to replace or complete claims that cited only a design paper or an unstated evidence gap. Each was resolved through live PubMed E-utilities during the audit session.

• Park SJ, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403:1753-1765. PMID 38604213 — tags: [pathophysiology-and-plaque-biology, clinical-trials-landscape] — cited by: wiki/pathophysiology-and-plaque-biology.md, wiki/clinical-trials-landscape.md
• Ridker PM, et al. Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction. JAMA Cardiol. 2026;11:89-97. PMID 41369941 — tags: [inflammation-and-residual-risk] — cited by: wiki/inflammation-and-residual-risk.md
• Cho L, et al. Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial. Atherosclerosis. 2026;418:120796. PMID 42250319 — tags: [guidelines] — cited by: wiki/guidelines.md